Literature DB >> 17267300

Liquid chromatography-tandem mass spectrometry assay for the quantitation of beta-dihydroartemisinin in rat plasma.

Jie Xing1, Hong-Xia Yan, Rui-Li Wang, Li-Feng Zhang, Shu-Qiu Zhang.   

Abstract

Dihydroartemisinin (DHA) is a sesquiterpene used in the world as an antimalarial. To evaluate the pharmacokinetics of dihydroartemisinin in rats, a sensitive and specific liquid chromatography/tandem mass spectrometric (LC-MS/MS) method was developed and validated for the quantitation of dihydroartemisinin in rat plasma. For detection, a Sciex API 4000 LC-MS/MS with a TurboIonSpray ionization (ESI) inlet in the positive ion-multiple reaction monitoring (MRM) mode was used. The plasma samples were pre-treated by a simple liquid-liquid extraction with diethyl ether. The statistical evaluation for this method reveals excellent linearity, accuracy and precision for the range of concentrations 0.2-100.0 ng/mL. The method had a lower limit of quantification (LLOQ) of 0.2 ng/mL for beta-dihydroartemisinin in 100 microL of plasma. The method was successfully applied to the characterization of the pharmacokinetic profile of beta-dihydroartemisinin in rats after oral administration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17267300     DOI: 10.1016/j.jchromb.2007.01.017

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  2 in total

1.  Potent in vivo anti-malarial activity and representative snapshot pharmacokinetic evaluation of artemisinin-quinoline hybrids.

Authors:  Marli C Lombard; David D N'Da; Christophe Tran Van Ba; Sharon Wein; Jennifer Norman; Lubbe Wiesner; Henri Vial
Journal:  Malar J       Date:  2013-02-21       Impact factor: 2.979

2.  Quantification of artemisinin in human plasma using liquid chromatography coupled to tandem mass spectrometry.

Authors:  N Lindegardh; J Tarning; P V Toi; T T Hien; J Farrar; P Singhasivanon; N J White; M Ashton; N P J Day
Journal:  J Pharm Biomed Anal       Date:  2008-12-24       Impact factor: 3.935

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.